Veru (NASDAQ:) Inc., a pharmaceutical firm, has acquired a notification from Nasdaq on Thursday, August 29, 2024, relating to non-compliance with the change’s minimal bid worth rule. The corporate’s frequent inventory, traded beneath the ticker VERU on the Nasdaq Capital Market, has been closing beneath the required $1.00 per share for 30 consecutive enterprise days.
Regardless of the discover, Veru’s inventory will stay listed on the Nasdaq Capital Marketplace for now. The corporate has been granted a 180-day interval, till February 25, 2025, to regain compliance with the minimal bid worth rule. To attain compliance, the closing bid worth of Veru’s frequent inventory should meet or exceed $1.00 per share for at the very least 10 consecutive buying and selling days inside this era. Nasdaq could select to increase this length at its discretion.
Ought to Veru fail to fulfill the requirement by the February deadline, it might be eligible for a further 180-day compliance interval. Nevertheless, to qualify for this extension, the corporate should meet all different preliminary itemizing requirements for the Nasdaq Capital Market, apart from the bid worth requirement, and should specific its intention to resolve the deficiency, which can embrace a reverse inventory break up if obligatory.
If Veru Inc. is unable to regain compliance in the course of the allotted time frames, it faces the chance of being delisted from the Nasdaq. This growth was confirmed in a submitting with the Securities and Alternate Fee (SEC) on Friday, August 30, 2024, by Michele Greco, the Chief Monetary Officer and Chief Administrative Officer of Veru Inc.
The corporate, initially referred to as Feminine Well being Co, and earlier than that as Wisconsin Pharmacal Firm Inc, is headquartered in Miami, Florida, and operates beneath the SIC code for Pharmaceutical Preparations [2834].
In different latest information, Veru Inc. has terminated its Open Market Gross sales Settlement with Jefferies LLC, a transfer marking a big shift in its capital-raising methods. This growth is alongside the pharmaceutical firm’s enlargement of its Board of Administrators with the appointment of Loren Mark Katzovitz, and the challenges confronted in attaining the required quorum for its 2024 Annual Assembly of Shareholders.
By way of analyst rankings, Jefferies revised its worth goal for Veru from $1.20 to $1.00, sustaining a Maintain score, whereas Oppenheimer lowered its goal from $7.00 to $5.00, sustaining an Outperform score. Moreover, Veru is conducting a Section IIB medical trial to judge enobosarm for weight problems therapy, led by weight problems professional Dr. Steven B. Heymsfield.
This text was generated with the assist of AI and reviewed by an editor. For extra info see our T&C.
